FDA cites Catalent Indiana issues in Scholar Rock’s SMA drug review; European approval decision expected in 2026, with Germany as the launch market.
Scholar Rock’s Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Where Today's News Shapes Tomorrow
